LIXTE Biotechnology Holdings, a clinical-stage pharmaceutical company trading on NASDAQ as LIXT, announced its sponsorship of the inaugural Good Health: Mind, Body & Soul Summit. The invitation-only event, scheduled for February 19 at Morehouse College in Atlanta, brings together leaders in health, culture, science, and community to advance health equity for Black men and families. The summit is inspired by the music, legacy, and lived experiences of the iconic hip-hop group De La Soul, specifically their song "Good Health" written following the passing of founding member David Jolicoeur.
Developed in collaboration with Blacksmith holdings, the program reflects De La Soul's evolution from musical pioneers to wellness advocates. Summit discussions will span critical health topics including cancer, heart disease, mental health, addiction, sleep, relationships, and intergenerational wellness. This comprehensive approach addresses multiple dimensions of health disparities that disproportionately affect Black communities.
LIXTE stated the summit aligns with its mission as a clinical-stage pharmaceutical company advancing cancer care through its first-in-class oncology compound LB-100 and its European research subsidiary, LIORA. The company emphasized creating a space to connect scientific innovation with communities most impacted by health disparities. This sponsorship represents a strategic alignment between pharmaceutical research and community health initiatives.
LIXTE Biotechnology Holdings focuses on new targets for cancer drug development and developing and commercializing cancer therapies. The company has demonstrated that its lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data available at https://www.lixte.com, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
The company's lead compound represents a pioneering effort in an entirely new field of cancer biology called activation lethality, advancing a new treatment paradigm covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. This research approach complements the summit's focus on addressing cancer disparities within Black communities.
The sponsorship announcement includes forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, involving risks, uncertainties, and other factors that may cause actual results to differ materially from expressed expectations. These statements are subject to various factors beyond management's control, including risks discussed in the company's SEC filings available through http://IBN.fm/Disclaimer. The company undertakes no duty to update this information unless required by law.
The Good Health: Mind, Body & Soul Summit represents a significant intersection of pharmaceutical innovation and community health advocacy. By sponsoring this event, LIXTE Biotechnology demonstrates commitment to addressing health disparities through both scientific research and community engagement. The summit's focus on comprehensive wellness—from physical health conditions like cancer and heart disease to mental health and relationships—acknowledges the multifaceted nature of health equity challenges.
This initiative has implications for how pharmaceutical companies can engage with communities affected by health disparities. Rather than focusing solely on drug development, LIXTE's sponsorship suggests a broader approach to healthcare that includes education, community dialogue, and addressing social determinants of health. The collaboration with cultural icons like De La Soul provides a unique platform for reaching communities that have historically experienced barriers to healthcare access and information.
For the pharmaceutical industry, this model of community engagement alongside scientific research could influence how companies approach health equity initiatives. The summit's location at Morehouse College, a historically Black institution, further emphasizes the commitment to engaging directly with affected communities. As health disparities continue to be a significant public health challenge, partnerships between research institutions, pharmaceutical companies, and community organizations may become increasingly important for developing comprehensive solutions.
